Sugi Predict

Sugi Predict / Compounds / SCHEMBL3107141

SCHEMBL3107141

SCHEMBL3107141

CC1(C)CN(c2ccc3nc(-c4ccccc4)c(-c4ccncc4)n3n2)CCN1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ CSNK1E P49674 11/20 1.00
▸ RIPK3 Q9Y572 7/20 0.58
▸ HASPIN Q8TF76 1/20 0.45
▸ LATS1 O95835 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744576 0.96 CSNK1E (0.92) CSNK1ERIPK3HASPINLATS1
SCHEMBL1744530 0.91 CSNK1E (0.84) CSNK1ERIPK3HASPINLATS1
SCHEMBL3110570 0.90 CSNK1E (1.00) CSNK1ERIPK3LATS1
SCHEMBL3116817 0.88 CSNK1E (1.00) CSNK1ERIPK3HASPINLATS1
SCHEMBL3111989 0.87 CSNK1E (1.00) CSNK1ERIPK3HASPINLATS1
SCHEMBL3105787 0.87 CSNK1E (0.81) CSNK1ERIPK3HASPINLATS1
SCHEMBL1746568 0.87 CSNK1E (0.77) CSNK1ERIPK3HASPINLATS1
SCHEMBL1743660 0.86 CSNK1E (0.75) CSNK1ERIPK3HASPINLATS1
SCHEMBL1745973 0.85 CSNK1E (0.73) CSNK1ERIPK3LATS1
SCHEMBL3119060 0.84 CSNK1E (0.90) CSNK1ERIPK3HASPINLATS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170889-B1 6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2016-08-17 — — EP claimed
US-8846676-B2 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2014-09-30 — — US claimed
US-8354405-B2 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-01-15 — — US claimed
US-20130012516-A1 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-01-10 — — US claimed
US-20100179154-A1 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-07-15 — — US claimed
US-20210177847-A1 Compounds for treatment of diseases related to DUX4 expression Facio Intellectual Property B.V. (NL) 2021-06-17 — — US disclosed
US-10973820-B2 Compounds for treatment of diseases related to DUX4 expression Facio Intellectual Property B.V. (NL) 2021-04-13 — — US disclosed
WO-2020249717-A1 CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER Facio Intellectual Property B.V. (NL) 2020-12-17 — — WO disclosed
WO-2019115711-A1 COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION Facio Intellectual Property B.V. (NL) 2019-06-20 — — WO disclosed
EP-3498278-A1 COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION Facio Intellectual Property B.V. (NL) 2019-06-19 — — EP disclosed
US-20190175596-A1 Compounds for treatment of diseases related to DUX4 expression Facio Intellectual Property B.V. (NL) 2019-06-13 — — US disclosed
EP-2170889-B1 6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2016-08-17 — — EP disclosed
US-8846676-B2 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2014-09-30 — — US disclosed
US-8354405-B2 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-01-15 — — US disclosed
US-20130012516-A1 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-01-10 — — US disclosed
US-20100179154-A1 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-07-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190175596-A1 Compounds for treatment of diseases related to DUX4 expression ZFX, MTPN, UTRN CSNK1E 2897/4885RIPK3 3485/4885HASPIN 2595/4885
US-20210177847-A1 Compounds for treatment of diseases related to DUX4 expression SMN1; SMN2, UTRN, DDX21 CSNK1E 2990/4885RIPK3 3657/4885HASPIN 2902/4885
US-10973820-B2 Compounds for treatment of diseases related to DUX4 expression ZFX, MTPN, UTRN CSNK1E 2897/4885RIPK3 3485/4885HASPIN 2595/4885
US-20130012516-A1 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CBR3, DHFR, IL4I1 CSNK1E 555/4885RIPK3 3076/4885HASPIN 2666/4885
US-20100179154-A1 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CBR3, DHFR, IL4I1 CSNK1E 555/4885RIPK3 3076/4885HASPIN 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.